Overview

Amylin is the pancreatic hormone co-secreted with insulin that signals meal termination through a pathway separate from GLP-1. Combining the two mechanisms is the leading strategy for pushing weight loss past the incretin ceiling.

Investigational — not approvedInvestigational. Not lawfully available for human use.

At a glance

Regulatory status	Phase 3 (REDEFINE program) as a fixed combination with semaglutide. Not approved.
Drug class	Long-acting amylin analog
Route	Subcutaneous, once weekly (investigational)
Half-life	~7 days
Evidence rating	3/5 Moderate Evidence rating 3 out of 5: Moderate Small or early-phase human trials, or good controlled topical human data.
Studied in	REDEFINE phase 3 program in obesity; earlier phase 2 combination trials.

How it works

Activates amylin and calcitonin receptor complexes in the area postrema, slowing gastric emptying and producing satiation. Because the receptor population differs from GLP-1, effects are additive rather than redundant.

Evidence base

Rated 3 of 5 — Moderate. Small or early-phase human trials, or good controlled topical human data.

Phase 3 topline data reported; full peer-reviewed publication and regulatory review pending.

Benefits & potential uses

Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.

Additive weight loss with semaglutide Moderate evidence

Combination phase 3 data reported mean weight reduction above 20%, exceeding either component alone.
Complementary satiety mechanism Preliminary

Amylin signalling may preserve efficacy where GLP-1 response plateaus.
Possible lean-mass sparing Preliminary

Amylin analogs have been hypothesised to shift the fat-to-lean loss ratio favourably; this remains under investigation.

Risks, cons & cautions

Bars indicate seriousness: three = serious or common, two = moderate, one = minor.

Not approved Serious

No regulatory authorisation anywhere; safety profile is still being characterised.
GI adverse effects Moderate evidence

Nausea and vomiting remain the dominant tolerability limit in combination.
Variable individual response Moderate evidence

Phase 3 results showed a wide response distribution and notable proportions of participants not reaching target doses.
Grey-market availability Serious

Sold illicitly as a "research peptide" with no quality control.

Who should avoid it

Use outside clinical trials

If used under medical supervision, monitor

Not applicable outside trials

Regulatory & legal status

Investigational. Not lawfully available for human use.

Infographic

Cagrilintide — benefits & risks at a glance Download SVG

Where to read further

We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.

weight lossamylininvestigationalcombination

Related peptides in Metabolic & Weight

Terms used on this page

Satiety vs Satiation: Satiation is the set of signals that ends a meal in progress, while satiety is the post-meal inhibition that determines how long it takes before eating begins again.
The Incretin Effect: The incretin effect is the larger insulin response to oral glucose than to intravenous glucose matched for the same blood glucose profile, and it is mediated mainly by GLP-1 and GIP.
Amylin: Amylin is a 37-residue hormone co-secreted with insulin from pancreatic beta cells that slows gastric emptying, suppresses glucagon and signals meal termination.
Glucagon-Like Peptide-1 (GLP-1): Glucagon-like peptide-1 is an incretin hormone released by intestinal L-cells after a meal that stimulates glucose-dependent insulin secretion and suppresses appetite.
Gastric Emptying: Gastric emptying is the rate at which stomach contents pass into the duodenum, a major determinant of postprandial glucose and of incretin therapy tolerability.
Phase 3 Trial: A Phase 3 trial is the large confirmatory study, powered for a prespecified clinical endpoint, on which a marketing application and the resulting product label are built.

This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.